Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,937
datasets available to search
ShareScore release 0.9.0
Dataset results
6,937 results for “metastatic cancer”
Ergolide Mediates Anti-Cancer Effects on Metastatic Uveal Melanoma Cells and Modulates their Cellular and Extracellular Vesicle proteomes
<p>Underlying dataset and extended dataset of the results described in the article "Ergolide Mediates Anti-Cancer Effects on Metastatic Uveal Melanoma Cells and Modulates their Cellular and Extracellular Vesicle proteomes".</p>
Supplementary Figures, Files and Datasets: Reduction of Metastasis via Epigenetic Modulation in a Murine Model of Metastatic Triple Negative Breast Cancer (TNBC)
<p>*denotes authors contributed equally to this work</p> <p>FileS1_Figures_Proofread.pdf: (Updated) Supplementary Figures (Figure S1: RNA-sequencing experimental design; Figure S2: Experiments measuring proliferation between drug-treated and control conditions indicate no significant difference 6 hrs. after scratch; Figure S3: Effect of 4SC-202 treatment on 4T1 tumor volume in mice; Figure S4: Differential expression between 4SC-202- and Vorinostat-treated 4T1 tumors; Figure S5: Top underexpressed differentially expressed genes 4SC-202 vs Control; Figure S6: HDACi target genes are not differentially expressed in RNA-sequencing data from 4SC-202-treated mice relative to control mice; Figure S7: Differential expression and expression of genes implicated gene ontology biological processes of interest; Figure S8: IPA visualization of the Regulation of Epithelial Mesenchymal Transition By Growth Factors Pathway emphasizing influence of 4SC-202-induced consensus DEGs; Figure S9: 4SC-202 modulates gene networks related to Cancer, Endocrine System Disorders, and Organismal Injury and Abnormalities; Figure S10: 4SC-202 modulates gene networks related to Cancer, Cellular Movement, and Organismal Injury and Abnormalities; Figure S11: 4SC-202 modulates gene networks related to Cell-mediated Immune Response, Cellular Movement, and Hematological System Development and Function; Figure S12: 4SC-202 differentially modulates gene networks related to Cellular Movement, Hematological System Development and Function, and Immune Cell Trafficking relative to Vorinostat); File S2: DAVID 4SC vs. Control 70DEG results: DAVID Annotation 4SC-202 vs Control 70 DEGs: Full functional annotation clustering results from DAVID Bioinformatics Resource for the 4SC-202-induced, consensus differentially expressed genes.; File S3: DAVID 4SC vs. Vori 33 DEGs results: DAVID Annotation 4SC-202 vs Control 33 DEGs: Full functional annotation clustering results from DAVID Bioinformatics Resource for the 4SC-202 versus Vorinostat consensus differentially expressed genes.; File S4: IPA 70 All Results: IPA Canonical Pathways Enrichment 70 DEGs: Full Ingenuity Pathway Analysis (IPA) canonical pathways enrichment results for the 4SC-202-induced, consensus differentially expressed genes.; File S5: IPA 33 Summary: Ingenuity Pathway Analysis (IPA) summary of the enrichment results for the 4SC-202-induced, consensus differentially expressed genes against Vorinostat.; File S6: Experiment RIN Numbers: RNA extraction quality control step, one of the various steps of quality control within the RNA-sequencing workflow. These RNA Integrity numbers are from the Agilent 2100 Bioanalyzer that looks for RNA contamination and degradation.; File S7: 4SC vs. Control all DEGs: Workflow results including all DEGs for 4SC-202 vs Control: Full excel file that contains all of the DEGs from the results of all workflows for 4SC-202.</p>
Structural modelling results to accompany the paper "Uncommon mutational profiles of metastatic colorectal cancer detected during routine genotyping using next generation sequencing: an update"
<p>This repository contains the results of modelling missense mutants in KRAS, NRAS and BRAF observed in our study in the corresponding protein structures. Modelling was performed using FoldX.</p>
Dataset on prognostic factors in patients with metastatic castration-resistant prostate cancer undergoing radioligand therapy with [177Lu]Lu-PSMA-617
<p>This upload provides Open Data associated with the publication "Prognostic value of the De Ritis ratio for overall survival in patients with metastatic castration-resistant prostate cancer undergoing [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy" by Gaal S <em>et al.</em> (2023).</p> <p>The upload contains the anonymized dataset of 91 patients analyzed in this publication with all variables that are required to reproduce the results.</p> <p>However, to fully comply with requirements for data anonymization, the patients' age was categorized into groups spanning 5 years each. A dataset with the age variable in exact years can be obtained from the corresponding author (julian.rogasch@charite.de) upon reasonable request.</p> <p>Besides the dataset, this upload provides a dictionary to explain all variables and their categories.</p>
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
ClinicalTrials.gov study NCT04484142. IPD Sharing: YES. Countries: 10. Publications: 1.
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
ClinicalTrials.gov study NCT00272987. IPD Sharing: YES. Countries: 2. Publications: 1.
Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2
ClinicalTrials.gov study NCT00281658. IPD Sharing: YES. Countries: 8. Publications: 2.
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
ClinicalTrials.gov study NCT01160211. IPD Sharing: YES. Countries: 29. Publications: 2.
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic S
ClinicalTrials.gov study NCT01808573. IPD Sharing: YES. Countries: 28. Publications: 2.
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT03088540. IPD Sharing: YES. Countries: 24. Publications: 4.
68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
ClinicalTrials.gov study NCT03490032. IPD Sharing: YES. Countries: 1. Publications: 0.
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
ClinicalTrials.gov study NCT03529110. IPD Sharing: YES. Countries: 15. Publications: 9.
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT04619004. IPD Sharing: YES. Countries: 16. Publications: 2.
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT04644237. IPD Sharing: YES. Countries: 10. Publications: 2.
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
ClinicalTrials.gov study NCT02975934. IPD Sharing: YES. Countries: 12. Publications: 3.
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
ClinicalTrials.gov study NCT01698918. IPD Sharing: YES. Countries: 13. Publications: 1.
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
ClinicalTrials.gov study NCT01852292. IPD Sharing: UNDECIDED. Countries: 18. Publications: 2.
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and W
ClinicalTrials.gov study NCT02485691. IPD Sharing: YES. Countries: 13. Publications: 5.
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT00667251. IPD Sharing: YES. Countries: 21. Publications: 3.
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT00820222. IPD Sharing: UNDECIDED. Countries: 14. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.